



Dag van de Tips

28 September 2019 - Gent



Thomas Lienard
CEO Bone Therapeutics



*New frontiers in orthopaedics
and bone diseases*

DISCLAIMER

This presentation has been prepared by Bone Therapeutics SA (the "Company") to provide an overview of the Company (and, together with its shareholders, subsidiaries and associated companies, the "Group"). For the purposes of this notice, "Presentation" means this document, its contents or any part of it, any oral presentation, any question or answer session and any written or oral material discussed or distributed during the Presentation meeting. This Presentation may not be copied, distributed, reproduced or passed on, directly or indirectly, in whole or in part, or disclosed by any recipient, to any other person (whether within or outside such person's organisation or firm) or published in whole or in part, for any purpose or under any circumstances. This Presentation is an advertisement and not a prospectus. Save as set out below, the Presentation has been prepared on the basis of information held by the Group and also from publicly available information. This information, which does not purport to be comprehensive, has not been independently verified by or on behalf of the Group. The Presentation does not constitute an audit or due diligence review and should not be construed as such.

This Presentation contains information on the Company's markets and competitive position, and more specifically, on the size of its markets. This information has been drawn from various sources or from the Company's own estimates. Investors should not base their investment decision on this information. This Presentation also contains certain forward-looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "plans", "may", "will" or "should" or, in each case, their negative or other variations or comparable terminology or by their context. These statements are not guarantees of the Company's future performance. These forward-looking statements relate to the Company's future prospects, developments and marketing strategy and are based on analysis of estimates not yet determinable. Forward-looking statements are subject to a variety of risks and uncertainties as they relate to future events and are dependent on circumstances that may or may not materialize in the future. The Company draws your attention to the fact that forward-looking statements cannot under any circumstance be construed as a guarantee of the Company's future performance and that the Company's actual financial position, results and cash flow, as well as the trends in the sector in which the Company operates may differ materially from those proposed or reflected in the forward-looking statements contained in this document and the accompanying oral presentation. Furthermore, even if the Company's financial position, results, cash-flows and developments in the sector in which the Company operates were to conform to the forward-looking statements contained in this document and the accompanying oral presentation, such results or developments cannot be construed as a reliable indication of the Company's future results or developments. Certain figures and numbers appearing in this document and the accompanying oral presentation have been rounded. Consequently, the total amounts and percentages appearing in the tables are therefore not necessarily equal to the sum of the individually rounded figures, amounts or percentages.

Information relating to markets and other industry data pertaining to the Company's business included in this presentation has been obtained from internal surveys, scientific publications and publicly available information. The main sources for industry information were peer-reviewed publications, sector association studies and government statistics. Bone Therapeutics has not independently verified information obtained from industry and public sources. Certain other information in this presentation regarding the industry reflects the Company's best estimates based upon information obtained from industry and public sources. Information from the Company's internal estimates and surveys has not been verified by any independent sources."

The information included in this presentation has been provided to you solely for your information and background and is subject to updating, completion, revision and amendment and such information may change materially. No person is under any obligation to update or keep current the information contained in this presentation and any opinions expressed in relation thereto are subject to change without notice. No representation or warranty, express or implied, is made as to the fairness, accuracy, reasonableness or completeness of the information contained herein. Neither the Company nor any other person accepts any liability for any loss howsoever arising, directly or indirectly, from this presentation or its contents.

This document and its contents may not be viewed by persons within the United States (within the meaning of Regulation S under the Securities Act) other than (i) by QIBs (Qualified Institutional Buyers) or (ii) in "offshore transactions" within the meaning of Regulation S. This document and any materials distributed in connection with this document are not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe any such restrictions. This document does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any securities of the Company nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Company, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.

By reviewing this document and attending the meeting where this Presentation is made, you warrant, represent, acknowledge and agree to and with the Company and the Banks that (i) you and any persons you represent are either (a) QIBs or (b) are located outside the United States, (ii) you have read, agree to and will comply with the contents of this disclaimer including, without limitation, the obligation to keep this Presentation and its contents confidential, and that you will abide by the terms of any additional agreement in respect of confidentiality and non-disclosure which you may be asked to sign and (iii) you will not at any time have any discussion, correspondence or contact concerning the information in this Presentation with any third party without the prior written consent of the Company.

EEN GEDREVEN MANAGEMENT TEAM



Benoit Moreaux, PhD
*Chief Scientific and
Technology Officer*



Jean-Luc Vandebroek
Chief Financial Officer



Thomas Lienard
Chief Executive Officer



Olivier Godeaux, MD
Chief Medical Officer



Linda Lebon
*Chief Regulatory
Affairs Officer*



- Industrie-expertise om Bone Therapeutics tot het stadium van commercialisering van de eerste producten te brengen
- Met ruime ervaring in klinische ontwikkeling, farmaceutische regelgeving, zakelijke ontwikkeling en biotechnologische productie

EEN ERVAREN RAAD VAN BESTUUR



Claudia D'Augusta
Onafhankelijk Bestuurslid



Gloria Matthews
Onafhankelijk Bestuurslid



Damian Marron
Onafhankelijk Bestuurslid



Jean St  phenne
Voorzitter van de Raad van Bestuur



Jean-Paul Prieels
Onafhankelijk Bestuurslid



Thomas Lienard
Uitvoerend Leidinggevend Bestuurslid



Jean-Luc Vandebroek
Uitvoerend Leidinggevend Bestuurslid





HERTEKENEN VAN HET ORTHOPEDISCHE LANDSCHAP

tot

EEN WERELD WAAR ONZE BAANBREKENDE BOTTHERAPIEËN
MENSENLEVEN HELPEN HEROPBOUWEN

BONE THERAPEUTICS IN EEN NOTENDOP



Minimaal invasieve
allogene botceltechnologie & verrijkte proteïne-oplossing



Gericht op **orthopedische**
en **botaandoeningen**
met **hoge medische noden**



Gevorderde klinische pijplijn
gericht op **3 indicaties**,
waarvan er **2 fase II / III** ingaan



Sterk IP Portofolio,
Infrastructuur en know-how in
de **productie** van **celtherapeutische**
producten




Ervaren Management Team en Raad van Bestuur, en **goed opgeleide werknemers**
(~ 20% PhDs) met relevante industrie-expertise



Spin-off van ULB,
Genoteerd op **Euronext**
Brussel & Parijs


EEN GEVORDERDE KLINISCHE PIJPLIJN GERICHT OP GROTE ORTHOPEDISCHE AANDOENINGEN MET HOGE ONBEANTWOORDE MEDISCHE NODEN



ALLOB


EEN INNOVATIEF ALLOGEEN BOTCELTERAPIE-PLATFORM
GERICHT OP ORTHOPEDISCHE AANDOENINGEN
MET HOGE NODEN

GEBASEERD OP HET UNIEKE GEBRUIK VAN GEDIFFERENTIEERDE BOTVORMENDE CELLEN



MINIMAAL INVASIEVE TOEDIENING

- Snelle en eenvoudige toediening
- Geen open operatie
- Dagopname



VERTRAAGD HELENDE BREUKEN

EEN GROTE MARKT MET BEPERKTE THERAPEUTISCHE OPTIES



> 700.000 gevallen van vertraagd helende breuken per jaar wereldwijd




5+% stijging op jaarbasis van de markt



- “Wait & See” is huidige aanpak
- Hoge ziektelast



RESULTATEN FASE I/IIA STUDIE IN VERTRAAGD-HELENDE BREUKEN MET ALLOB

SIGNIFICANTE RADIOLOGISCHE EVOLUTIE IN DE GENEZING VAN DE BREUK



RESULTATEN FASE I/IIA STUDIE IN VERTRAAGD-HELENDE BREUKEN MET ALLOB

SIGNIFICANTE KLINISCHE VERBETERING IN ALGEMENE GEZONDSTOESTAND EN PIJN



JTA-004

EEN GEBRUIKSKLARE VERRIJKTE PROTEÏNE-OPLOSSING
VOOR EEN VEEL VOORKOMENDE KNIEAANDOENING

KNIE-ARTHROSE

MEEST VOORKOMENDE KNIEAANDOENING WERELDWIJD
MET GROTE ONVERVULDE NODEN



Meest voorkomende gewrichtsaandoening
27 miljoen gevallen in EU, VS en Japan



Geschatte jaarlijkse stijging 8+%



- Viscosupplement als een symptomatische behandeling
- Werking met een beperkte duur


JTA-004 EEN NIEUW INJECTEERBAAR PROTEINE-OPLOSSING

Een gebruiksklare, verrijkte proteïne-oplossing
bestaande uit

3 werkzame bestanddelen



*Verrijkte
proteïne-
oplossing*



Hyaluronzuur



Pijnstillend middel




BETERE PIJNVERLICHTING IN VERGELIJKING MET MARKTLEIDER



Significant sterkere pijnvermindering ten opzichte van marktleider

Post hoc analyse JTA-004 (pooled) vs Hylan G-F 20



2 PRODUCTEN KLAAR VOOR FASE II/III EIND 2019



ALLOB



Bot-
celtherapie

- Gedifferentieerde, actieve botvormende cellen
- Allogeen (uit beenmerg van een gezonde donor)
- Injecteerbaar (minimaal invasief)
- Economische, grootschalige productie
- Klaar voor gebruik
- Markten :
 - Breuken met een hoog risico op vertraagd en niet-helende breuken (>1M gevallen per jaar)
 - Procedures voor vertebrale fusie (~ 500k patiënten per jaar)


JTA-004



Verrijkte
proteïne-
oplossing


- Gepatenteerde samenstelling van 3 werkzame stoffen
- Handige, eenmalige injectie
- Pijnverzachend & smerende eigenschappen
- Betere pijnbestrijding versus marktleider
- Eenvoudig productieproces
- Markt : Artrose van de knie (~27M patiënten per jaar in de EU/VS/JAP)

BELANGRIJKSTE MIJLPALEN IN 2019 - 2020





Exploring new frontiers in orthopedics and bone diseases



Vragen ?



Contact

Thomas LIENARD

Chief Executive Officer

Jean-Luc VANDEBROEK

Chief Financial Officer

Telefoon: +32 (0) 71 12 10 00

Fax: +32 (0) 71 71 12 10 01

E-mail: info@bonetherapeutics.com

Website: www.bonetherapeutics.com



Wallonie

